860804-18-8

Bencycloquidium Bromide, also known as BCQB, is a muscarinic M3 antagonist potentially for the treatment of allergic rhinitis and chronic obstructive. Bencycloquidium bromide inhibits nasal hypersecretion in a rat model of allergic rhinitis. BCQB showed high affinity toward the M(3) receptor in Chinese hamster ovary (CHO) cells (M(3) pKi=8.21, M(2) pKi=7.21, and M(1) pKi=7.86); pA(2)=8.85, 8.71 and 8.57 in methacholine-induced contraction of trachea, ileum and urinary bladder, 8.19 in methacholine-induced bradycardia of right atrium in vitro, respectively.

Bencycloquidium bromide, a muscarinic M(3) receptor antagonist, is an anticholinergic compound that acts as an anticholinergic bronchodilator. Bencycloquidium bromide can be used in the study for rhinitis[1][2].

[1] Qin Xu, et al. Determination of bencycloquidium bromide in rat plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):209-14. DOI:10.1016/j.jchromb.2006.09.028
[2] Jun-Xia Jiang, et al. Characterization of bencycloquidium bromide, a novel muscarinic M(3) receptor antagonist in guinea pig airways. Eur J Pharmacol. 2011 Mar 25;655(1-3):74-82. DOI:10.1016/j.ejphar.2011.01.017